NCT00699751 2026-02-23
ALSYMPCA
Bayer
Phase 3 Completed
Clinical Trials
10 trialsNCT00667199 2023-04-19
BAY88-8223, Does Response Study in HRPC Patients
Bayer
Phase 2 Completed
NCT01741116 2021-02-18
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer
Korean Cancer Study Group
Phase 2 Completed
NCT00477529 2019-11-22
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
Celgene
Phase 1/2 Completed
NCT00286091 2018-10-17
Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer
Amgen
Phase 3 Completed
NCT00928252 2017-08-14
Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer
Queen's Medical Center
Phase 1/2 Completed
NCT00629525 2015-03-03
RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
Duke University
Phase 2 Completed
NCT01215799 2011-12-15
PROACT
CytRx
Phase 2 Completed
NCT00407251 2010-11-05
Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy
British Columbia Cancer Agency
Phase 2 Completed
NCT00286806 2010-08-24
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
Ascenta Therapeutics
Phase 1/2 Completed